Operating CF
$13.31B
Capex
−$1.40B
Free Cash Flow
$11.91B
FCF Margin
+89.5%
Cash flow waterfall for Bristol-Myers Squibb (BMY) — TTM through Q1 2026
Free cash flow: $11.91B
Cash flow breakdown for Bristol-Myers Squibb (BMY) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $13.31B | $13.31B |
| Capital Expenditure | −$1.40B | $11.91B |
| Free Cash Flow | $11.91B | $11.91B |
| Acquisitions | −$3.90B | $8.01B |
| Other Investing | $1.53B | $9.54B |
| Dividends Paid | −$5.07B | $4.47B |
| Net Debt Change | −$5.72B | −$1.25B |
| Other Financing & FX | −$42.00M | −$1.29B |
| Net Cash Decrease | −$1.29B | −$1.29B |
- Operating Cash Flow$13.31B
- Capital Expenditure−$1.40B
- Free Cash Flow$11.91B
- Acquisitions−$3.90B
- Other Investing$1.53B
- Dividends Paid−$5.07B
- Net Debt Change−$5.72B
- Other Financing & FX−$42.00M
- Net Cash Decrease−$1.29B
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement